MedTrace Logo

Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study

NCT01152996 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1075

Last updated 2014-05-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the long-term safety and tolerability of vortioxetine, once daily (QD), in participants with major depressive disorder.

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

Vortioxetine

Vortioxetine tablets

Sponsors & Collaborators

Principal Investigators

  • Senior Medical Director · Takeda

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
77 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2013-05-31
Completion
2013-05-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01152996 on ClinicalTrials.gov